Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer

Yousif Abubakr,1 Yasar Albushra2

1Nation of Cancer Disparities, Kimmel Cancer Center at Jefferson, Thomas Jefferson University, Philadelphia, PA, USA; 2Department of Medical Oncology, King Faisal Specialist Hospital & Research Centre, Saudi Arabia

Correspondence: Yasar Albushra, Department of Medical Oncology, King Faisal Specialist Hospital & Research Centre, Saudi Arabia.

E-mail: drhammor@yahoo.co.uk

Key words: advanced breast cancer, hormonal therapy, antiestrogen, anti-HER2 therapy.

See the Retraction note at: http://dx.doi.org/10.4081/oncol.2014.255